Amsterdam, the Netherlands, and Holzgerlingen, Germany, December 19, 2017, 02:00 a.m. EST -- Curetis N.V. (the "Company" and, together with Curetis GmbH, "Curetis"), a developer of next-level molecular diagnostic solutions, today announced that the Company is going to attend several industry conferences in the first quarter of 2018.
J.P. Morgan 36th Annual Healthcare Conference, January 08-10, 2018 - San Francisco, CA, USA - one-on-one investor meetings
Reanimation Congress 2018, January 24-26, 2018 - Paris, France: booth number 43b, Hall 7, Congress Centre: Paris Expo - Porte de Versailles
Degroof Petercam Life Sciences Investor Day, February 01, 2018 - Brussels, Belgium - one-on-one investor meetings
BioCapital Europe, February 06, 2018 - Amsterdam, The Netherlands - company presentation and one-on-one investor meetings
28th Syposium Intensivmedizin + Intensivpflege, February 14-16, 2018 - Bremen, Germany: booth number S15, Hall 4, Congress Centre: Messe Bremen
DGHM 2018 - 70th Annual Meeting of the German Society for Hygiene and Microbiology, February 19-21, 2018 - Bochum, Germany: booth number 12,
11th Berlin Conference on Life Sciences - Novel Antimicrobials and AMR Diagnostics, March 02, 2018 - Berlin, Germany
Founded in 2007, Curetis is a molecular diagnostics company which focuses on the development and commercialization of reliable, fast and cost-effective products for diagnosing severe infectious diseases. The diagnostic solutions of Curetis enable rapid multi-parameter pathogen and antibiotic resistance marker detection in only a few hours, a process that today can take up to days or even weeks with other techniques.
To date, Curetis has raised EUR 44.3 million in an IPO on Euronext Amsterdam and Euronext Brussels and private equity funds of over EUR 63.5 million. Furthermore, Curetis has entered into a debt financing facility with EIB for up to EUR 25 million. The company is based in Holzgerlingen near Stuttgart, Germany. Curetis collaborates with Heraeus Medical, pharmaceutical companies, and has entered into several international distribution agreements covering many countries across Europe, the Middle East and Asia.
In 2017, Curetis established Ares Genetics GmbH, a wholly-owned subsidiary of Curetis GmbH in Vienna, Austria. Ares Genetics is dedicated to maximize the R&D and related scientific and business opportunities of the GEAR assets acquired in 2016 for the entire Curetis Group.
For further information, please visit www.curetis.com.
This document constitutes neither an offer to buy nor to subscribe securities and neither this document nor any part of it should form the basis of any investment decision in Curetis.
The information contained in this press release has been carefully prepared. However, Curetis bears and assumes no liability of whatever kind for the correctness and completeness of the information provided herein. Curetis does not assume an obligation of whatever kind to update or correct information contained in this press release whether as a result of new information, future events or for other reasons.
This press release includes statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "expects", "intends", "may", "will", or "should", and include statements Curetis makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. Curetis' actual results may differ materially from those predicted by the forward-looking statements. Curetis undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.
International Media & Investor Inquiries
Dr. Ludger Wess / Ines-Regina Buth
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68
U.S. Media & Investor Inquiries
The Ruth Group
Tel. +1 646 536 7012